Oral TYK2 Inhibition in Atopic Dermatitis

Phase 2 trial evaluated once-daily oral TYK2 inhibition in adults with moderate to severe AD.

1

The phase 2 trial demonstrated that oral ICP-332 significantly reduced atopic dermatitis severity and pruritus in adults.
2

At week 4, mean reductions in Eczema Area and Severity Index were 78% for the 80-mg dose and 73% for the 120-mg dose compared to 17% for placebo.
3

64% of patients receiving ICP-332 achieved an Eczema Area and Severity Index 75 response, compared to 8% with placebo.
4

Treatment-emergent adverse events occurred in 68% of placebo patients and 76% and 75% of those receiving ICP-332, all classified as mild or moderate.
5

The study supports further phase 3 trials to confirm ICP-332's efficacy and safety in treating moderate to severe atopic dermatitis.

1